Outcome of Women With Cervical Cancer
Conditions
Cervical Cancer
Conditions: official terms
Uterine Cervical Neoplasms
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case-Only, Time Perspective: Retrospective
Overall Status
Recruiting
Summary
Squamous cell carcinoma (SCC) of the cervix has showed a marked decline in developed countries over the past 40 years, however, there has also been an increase in relative and absolute incidence of adenocarcinoma and adenosquamous carcinoma (AC) of the uterine cervix over the same period.

Our understanding of the natural history and optimal management of AC is limited. It appears that AC and SCC of the cervix behave differently. They are different in epidemiology, prognostic factors, and patterns of failure after similar treatments. Available data suggest that they may also differ in their response to treatment. We postulate that new treatment strategies specifically tailored to AC should be explored.

However, there is few data about outcome of cervical cancer in Taiwan. So we propose this proposal for retrospective analysis of clinicopathological parameters and outcomes in patients of cervical cancer, especially for cervical adenocarcinoma and adenosquamous carcinoma.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 20 Years
Gender: Female
Criteria: Inclusion Criteria:

- Time interval: from 1991 to date.

- Comprehensive surgical staging, debulking procedure, radiotherapy or chemotherapy.

- All female patients with cervical cancer who underwent treatment for cervical cancer at Far Eastern Memorial Hospital.

- All the patients diagnosed as cervical cancer, especially for women with adeno- and adenosquamous carcinoma.

- To review:

1. Clinical data: including age at diagnosis, presenting symptoms, gravidity, parity, menstrual history, body mass index, history of diabetes, hypertension, personal history of cancer and staging.

2. Pathologic information: deep stromal invasion, lymph-vascular space invasion, lymph node involvement, parametrium invasion, vaginal cut end and tumor size.

3. Survival data: disease-free and overall survival.

4. Radiation report, Chemotherapy treatment, operation, discharge and admission note.

Exclusion Criteria:

- Not comprehensive staging/debulking procedure.

- Patients who died of postoperative complications within 30 days after surgery were excluded from the survival analysis.

- Female minors or disabled persons.
Location
Far Eastern Memorial Hospital
Banqiao, Taipei, Taiwan
Status: Recruiting
Contact: Sheng-Mou Hsiao, MD - +886-2-89667000 - smhsiao2@gmail.com
Start Date
January 2014
Sponsors
Far Eastern Memorial Hospital
Source
Far Eastern Memorial Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page